Immunisation with recombinant BCG expressing the cottontail rabbit papillomavirus (CRPV) L1 gene provides protection from CRPV challenge

V. A. Govan, N. D. Christensen, C. Berkower, W. R. Jacobs, A. L. Williamson

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Recombinant Bacille Calmette-Guerin (rBCG) could potentially be the vaccine vehicle of choice to deliver foreign antigens from multiple pathogens. In this study we have used the cottontail rabbit papillomavirus (CRPV) rabbit model to provide a "proof of concept" that immunisation with rBCG expressing the CRPV major capsid protein, L1 (rBCG/CRPVL1), will protect outbred New Zealand White rabbits against CRPV challenge. Rabbits immunised with rBCG/CRPVL1 (107 cfu/ml) were protected 5 weeks post-CRPV challenge. Rabbits immunised with rBCG/CRPVL1 (105 cfu/ml) had papillomas, which were smaller and took longer to appear than the control rabbits. None of the negative control rabbits vaccinated with rBCG expressing an irrelevant gene or PBS were protected from CRPV challenge. Sera from rabbits immunised with rBCG/CRPVL1 (107 cfu/ml) were able to neutralise 54.5% of CRPV at serum dilutions of 1:200. These results provide evidence that BCG could potentially be used as a vaccine delivery vehicle for human papillomavirus proteins as a possible prophylactic vaccine.

Original languageEnglish (US)
Pages (from-to)2087-2093
Number of pages7
JournalVaccine
Volume24
Issue number12
DOIs
StatePublished - Mar 15 2006

Fingerprint

Cottontail rabbit papillomavirus
Mycobacterium bovis
Immunization
immunization
rabbits
Rabbits
Genes
genes
vaccines
Vaccines
papilloma
New Zealand White rabbit
Papillomaviridae
coat proteins
Papilloma
Capsid Proteins
Serum
antigens
pathogens
Antigens

Keywords

  • CRPV
  • rBCG
  • Vaccine

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

Immunisation with recombinant BCG expressing the cottontail rabbit papillomavirus (CRPV) L1 gene provides protection from CRPV challenge. / Govan, V. A.; Christensen, N. D.; Berkower, C.; Jacobs, W. R.; Williamson, A. L.

In: Vaccine, Vol. 24, No. 12, 15.03.2006, p. 2087-2093.

Research output: Contribution to journalArticle

Govan, V. A. ; Christensen, N. D. ; Berkower, C. ; Jacobs, W. R. ; Williamson, A. L. / Immunisation with recombinant BCG expressing the cottontail rabbit papillomavirus (CRPV) L1 gene provides protection from CRPV challenge. In: Vaccine. 2006 ; Vol. 24, No. 12. pp. 2087-2093.
@article{14d656ccbae9443eb7187ede331811da,
title = "Immunisation with recombinant BCG expressing the cottontail rabbit papillomavirus (CRPV) L1 gene provides protection from CRPV challenge",
abstract = "Recombinant Bacille Calmette-Guerin (rBCG) could potentially be the vaccine vehicle of choice to deliver foreign antigens from multiple pathogens. In this study we have used the cottontail rabbit papillomavirus (CRPV) rabbit model to provide a {"}proof of concept{"} that immunisation with rBCG expressing the CRPV major capsid protein, L1 (rBCG/CRPVL1), will protect outbred New Zealand White rabbits against CRPV challenge. Rabbits immunised with rBCG/CRPVL1 (107 cfu/ml) were protected 5 weeks post-CRPV challenge. Rabbits immunised with rBCG/CRPVL1 (105 cfu/ml) had papillomas, which were smaller and took longer to appear than the control rabbits. None of the negative control rabbits vaccinated with rBCG expressing an irrelevant gene or PBS were protected from CRPV challenge. Sera from rabbits immunised with rBCG/CRPVL1 (107 cfu/ml) were able to neutralise 54.5{\%} of CRPV at serum dilutions of 1:200. These results provide evidence that BCG could potentially be used as a vaccine delivery vehicle for human papillomavirus proteins as a possible prophylactic vaccine.",
keywords = "CRPV, rBCG, Vaccine",
author = "Govan, {V. A.} and Christensen, {N. D.} and C. Berkower and Jacobs, {W. R.} and Williamson, {A. L.}",
year = "2006",
month = "3",
day = "15",
doi = "10.1016/j.vaccine.2005.11.029",
language = "English (US)",
volume = "24",
pages = "2087--2093",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "12",

}

TY - JOUR

T1 - Immunisation with recombinant BCG expressing the cottontail rabbit papillomavirus (CRPV) L1 gene provides protection from CRPV challenge

AU - Govan, V. A.

AU - Christensen, N. D.

AU - Berkower, C.

AU - Jacobs, W. R.

AU - Williamson, A. L.

PY - 2006/3/15

Y1 - 2006/3/15

N2 - Recombinant Bacille Calmette-Guerin (rBCG) could potentially be the vaccine vehicle of choice to deliver foreign antigens from multiple pathogens. In this study we have used the cottontail rabbit papillomavirus (CRPV) rabbit model to provide a "proof of concept" that immunisation with rBCG expressing the CRPV major capsid protein, L1 (rBCG/CRPVL1), will protect outbred New Zealand White rabbits against CRPV challenge. Rabbits immunised with rBCG/CRPVL1 (107 cfu/ml) were protected 5 weeks post-CRPV challenge. Rabbits immunised with rBCG/CRPVL1 (105 cfu/ml) had papillomas, which were smaller and took longer to appear than the control rabbits. None of the negative control rabbits vaccinated with rBCG expressing an irrelevant gene or PBS were protected from CRPV challenge. Sera from rabbits immunised with rBCG/CRPVL1 (107 cfu/ml) were able to neutralise 54.5% of CRPV at serum dilutions of 1:200. These results provide evidence that BCG could potentially be used as a vaccine delivery vehicle for human papillomavirus proteins as a possible prophylactic vaccine.

AB - Recombinant Bacille Calmette-Guerin (rBCG) could potentially be the vaccine vehicle of choice to deliver foreign antigens from multiple pathogens. In this study we have used the cottontail rabbit papillomavirus (CRPV) rabbit model to provide a "proof of concept" that immunisation with rBCG expressing the CRPV major capsid protein, L1 (rBCG/CRPVL1), will protect outbred New Zealand White rabbits against CRPV challenge. Rabbits immunised with rBCG/CRPVL1 (107 cfu/ml) were protected 5 weeks post-CRPV challenge. Rabbits immunised with rBCG/CRPVL1 (105 cfu/ml) had papillomas, which were smaller and took longer to appear than the control rabbits. None of the negative control rabbits vaccinated with rBCG expressing an irrelevant gene or PBS were protected from CRPV challenge. Sera from rabbits immunised with rBCG/CRPVL1 (107 cfu/ml) were able to neutralise 54.5% of CRPV at serum dilutions of 1:200. These results provide evidence that BCG could potentially be used as a vaccine delivery vehicle for human papillomavirus proteins as a possible prophylactic vaccine.

KW - CRPV

KW - rBCG

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=32844462492&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=32844462492&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2005.11.029

DO - 10.1016/j.vaccine.2005.11.029

M3 - Article

C2 - 16343704

AN - SCOPUS:32844462492

VL - 24

SP - 2087

EP - 2093

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 12

ER -